Publication | Closed Access

Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer

Advanced Breast CancerBreast OncologyMedicinePathologyBreast CancerHormone ReceptorsCancer TreatmentOncologyRadiation OncologyTumor BiologyEndocrine-related CancerNeoadjuvant Chemotherapy